Travoprost Ophthalmic Solution — FDA Drug Shortage

To Be Discontinued — Mylan Pharmaceuticals Inc., A Viatris Company

The FDA lists a drug shortage record for Travoprost Ophthalmic Solution (ophthalmic solution) from Mylan Pharmaceuticals Inc., A Viatris Company with status To Be Discontinued. The shortage was first posted on Jul 7, 2026.

Shortage details

Status
To Be Discontinued
Company
Mylan Pharmaceuticals Inc., A Viatris Company
Package NDC
0378-9651-32
Dosage Form
Ophthalmic Solution
Presentation
Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32)
Initial Posting
Jul 7, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.